Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at Gabelli upped their FY2017 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Thursday. Gabelli analyst K. Kedra now forecasts that the specialty pharmaceutical company will post earnings of ($2.45) per share for the year, up from their previous forecast of ($2.90). Gabelli also issued estimates for Collegium Pharmaceutical’s FY2018 earnings at ($1.65) EPS, FY2019 earnings at ($0.60) EPS, FY2020 earnings at $1.15 EPS and FY2021 earnings at $2.35 EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. During the same quarter in the prior year, the company posted ($1.13) earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 2814.6% on a year-over-year basis.
A number of other research analysts have also weighed in on COLL. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, July 25th. BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Monday, August 14th. HC Wainwright began coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, September 21st. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.33.
Collegium Pharmaceutical (NASDAQ COLL) opened at $14.16 on Monday. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $17.73.
Institutional investors have recently bought and sold shares of the business. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,163 shares during the last quarter. Voya Investment Management LLC acquired a new stake in Collegium Pharmaceutical in the second quarter valued at $125,000. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,422 shares during the last quarter. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after purchasing an additional 1,173 shares during the last quarter. Finally, UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 10,174 shares during the last quarter. 83.96% of the stock is currently owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.